文献速递MDS 与骨髓增殖性肿瘤白血病

ASXL1、SRSF2和EZH2突变在骨髓增生异常性肿瘤和急性髓系白血病染色质失调中的作用

The role of ASXL1, SRSF2, and EZH2 mutations in chromatin dysregulation of myelodysplastic neoplasia and acute myeloid leukemia.
PubMed 文献 · Leukemia · 2025-06-25

本文综述染色质调控基因ASXL1、SRSF2和EZH2突变在骨髓增生异常性肿瘤(MDS)和急性髓系白血病(AML)发病机制中的作用。这些突变被认定为不良预后标志物,通过影响组蛋白修饰和RNA剪接过程破坏正常基因表达。针对高风险患者的治疗选择仍然有限,维奈克拉联合低甲基化剂等新兴策略显示出前景。

要点

  • ASXL1、SRSF2和EZH2突变被认定为MDS/AML的不良预后标志物。
  • ASXL1突变增强组蛋白H2AK119去泛素化,损害造血干细胞分化。
  • SRSF2突变改变RNA结合特异性,诱导EZH2等关键基因异常剪接;EZH2功能缺失突变破坏PRC2介导的转录抑制。

核心结论

  • ASXL1、SRSF2和EZH2突变通过表观遗传机制参与MDS/AML发病,并被认定为不良预后标志物。
  • 针对携带这些突变的高风险患者,治疗选择仍然有限。
  • 维奈克拉联合低甲基化剂等新兴策略在改善这些突变相关的不良预后方面显示出前景。

研究设计与样本

  • 本文为综述,汇总近期关于表观遗传调控因子及其相互作用的研究发现。

主要发现

  • ASXL1突变增强组蛋白H2AK119去泛素化,导致基因表达改变和造血干细胞分化受损。
  • SRSF2突变改变RNA结合特异性,诱导EZH2等关键基因异常剪接。
  • EZH2功能缺失突变破坏PRC2介导的转录抑制,促进白血病进展。

关键数值与推荐

  • ASXL1、SRSF2和EZH2突变被认定为不良预后标志物。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mutations in chromatin-regulating genes play a critical role in the pathogenesis of myelodysplastic neoplasia (MDS) and acute myeloid leukemia (AML), as genetic mutations affecting chromatin structure and function are key drivers of these hematologic malignancies. Central to the discussion are key emerging genes such as ASXL1, SRSF2, and EZH2, which are recognized as adverse prognostic markers. Mutations in these genes, coupled with subsequent alterations in epigenetic mechanisms, disrupt normal gene expression by impairing histone modification and RNA splicing processes. Specifically, mutations in ASXL1 enhance removal of ubiquitylation at histone H2AK119, leading to altered gene expression and impaired hematopoietic stem cell differentiation. Mutations in SRSF2, an RNA splicing factor, alter RNA-binding specificity, inducing aberrant splicing of key genes such as EZH2. Loss-of-function mutations in EZH2 disrupt PRC2-mediated transcriptional repression, promoting leukemic progression. However, while the effects of these mutations are understood, treatment options for high-risk patients remain limited. Emerging strategies, such as venetoclax combined with hypomethylating agents, showing promise in mitigating the poor prognosis associated with these mutations. This review consolidates recent findings on these epigenetic regulators and their interactions, providing insights into the multifaceted mechanisms of leukemogenesis in the interest of inspiring targeted therapeutic strategies and bridging extant treatment gaps for MDS/AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Yu H, Hong J, Shin DY, et al. The role of ASXL1, SRSF2, and EZH2 mutations in chromatin dysregulation of myelodysplastic neoplasia and acute myeloid leukemia. Leukemia. 2025. PMID: 40562788. doi:10.1038/s41375-025-02657-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。